In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y.
Where this comes from
- Record sourced from PubMed, PMID 36877974.
- Also identified by DOI 10.7326/J23-0009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. <b>Empagliflozin in patients with chronic kidney disease.</b> N Engl J Med. 2023;388:117-27. 36331190.
Medical subject headings
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Renal Insufficiency, Chronic